WBP2 and breast carcinoma: The potential utilization of anti-WBP2 inhibitors as combinatorial therapy treatment is conceived from the observations that loss of WBP2 can increase sensitivity towards certain chemotherapeutic drugs such as doxorubicin, tamoxifen and trastuzumab in breast cancers [64,67,69].